These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 15183125

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
    Chen B, Zheng J, Zeng Y, Li B, Xie B, Zheng J, Zhou J, Zhang W.
    PLoS One; 2014 Aug 01; 9(12):e114074. PubMed ID: 25474307
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 28. The effect of monoclonal antibody cetuximab (C225) in combination with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer cell lines.
    Yuan HH, Han Y, Bian WX, Liu L, Bai YX.
    Pathology; 2012 Oct 01; 44(6):547-51. PubMed ID: 22935976
    [Abstract] [Full Text] [Related]

  • 29. Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro.
    Andersson U, Johansson D, Behnam-Motlagh P, Johansson M, Malmer B.
    Acta Oncol; 2007 Oct 01; 46(7):951-60. PubMed ID: 17917826
    [Abstract] [Full Text] [Related]

  • 30. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A.
    Clin Cancer Res; 2006 Jan 15; 12(2):617-25. PubMed ID: 16428508
    [Abstract] [Full Text] [Related]

  • 31. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC, Kaufmann SH.
    Cancer Res; 2001 Jan 15; 61(2):739-48. PubMed ID: 11212277
    [Abstract] [Full Text] [Related]

  • 32. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
    Pavillard V, Agostini C, Richard S, Charasson V, Montaudon D, Robert J.
    Cancer Chemother Pharmacol; 2002 Apr 15; 49(4):329-35. PubMed ID: 11914913
    [Abstract] [Full Text] [Related]

  • 33. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells.
    Azzariti A, Porcelli L, Gatti G, Nicolin A, Paradiso A.
    Biochem Pharmacol; 2008 Mar 01; 75(5):1035-44. PubMed ID: 18191814
    [Abstract] [Full Text] [Related]

  • 34. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Aug 01; 10(2):931-8. PubMed ID: 24840891
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
    Nanbu T, Umemura N, Ohkoshi E, Nanbu K, Sakagami H, Shimada J.
    Oncol Rep; 2018 Jan 01; 39(1):367-375. PubMed ID: 29192320
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
    Philippart P, Harper L, Chaboteaux C, Decaestecker C, Bronckart Y, Gordover L, Lesueur-Ginot L, Malonne H, Lavergne O, Bigg DC, da Costa PM, Kiss R.
    Clin Cancer Res; 2000 Apr 01; 6(4):1557-62. PubMed ID: 10778989
    [Abstract] [Full Text] [Related]

  • 39. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
    Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, Dimitroulakos J.
    Clin Cancer Res; 2005 Mar 15; 11(6):2398-407. PubMed ID: 15788691
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.